Response to ALK Inhibition

Response to ALK Inhibition

Panel A shows the best response of patients with ALK-positive tumors who were treated with crizotinib, as compared with pretreatment baseline. Numbers along the x axis indicate arbitrarily assigned subject numbers from 1 to 79. The bars indicate the percent change in tumor burden from baseline. Three study patients are not included in this plot: one patient was clinically assessed as having had a partial response, although the response was primarily in areas of nonmeasurable disease, so the patient was classified as having stable disease; two patients with abrupt clinical deterioration could not be assessed. Four patients had complete resolution of their target lesions but were classified as having had a partial response on the basis of stability in nontarget lesions. Eight patients had tumor shrinkage of more than 30% but were classified as having stable disease either because confirmatory scans were not available by the data-cutoff point (for five patients) or early restaging was performed at 6 weeks after crizotinib initiation (for three patients). The dashed line indicates a tumor reduction of 30% from baseline, the minimal percent decrease that constitutes a partial response, according to Response Evaluation Criteria in Solid Tumors. Panel B shows the results of CT with coronal reconstruction in a representative patient at baseline (left) and after two cycles of therapy (right). This patient had undergone previous left lower lobectomy.